11β,17,21-trihydroxy-1-methyl-pregna-1.4-dien-3.20-dion | 981-44-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 11β,17,21-trihydroxy-1-methyl-pregna-1.4-dien-3.20-dion
• 英文别名: (8S,9S,10S,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
• CAS: 981-44-2
• 化学式: C₂₂H₃₀O₅
• 分子量: 374.477
• InChiKey: VVNDBKDEDMTMHN-CWNVBEKCSA-N

物化性质

• 熔点：
  260 °C
• 沸点：
  575.4±50.0 °C(Predicted)
• 密度：
  1.28±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  27
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  94.8
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Methods for treating or reducing the risk of pain and inflammatory disorders by administering inhibitors of activated thrombin activatable fibrinolysis inhibitor
  申请人：——

  公开号：US20030035795A1

  公开（公告）日：2003-02-20

  The invention includes methods for treating or reducing the risk of inflammation in a patient which comprises treating the patient with an inhibitor of activated thrombin activatable fibrinolysis inhibitor. Such diseases include but are not limited to nephritis, systemic lupus erythematosus, rheumatoid arthritis, glomerulonephritis, and sacoidosis. The invention includes methods for treating or reducing the risk of pain in a patient which comprises treating the patient with an inhibitor of activated thrombin activatable fibrinolysis inhibitor. In one class of these methods, the inhibitor of activated thrombin activatable fibrinolysis inhibitor is selected from the group consisting of 2-(6-amino-pyridin-3-ylmethyl)-3-butyl-succinic acid, 2-(6-amino-pyridin-3-ylmethyl)-3-phenethyl-succinic acid, 2-(6-amino-pyridin-3-ylmethyl)-3-methyl-succinic acid, 2-(6-amino-5-methyl-pyridin-3-ylmethyl)-3-[(1-benzyloxycarbonylamino-2-methyl-propyl)hydroxy-phosphinoyl]-propionic acid, 2-(6-amino-pyridin-3-ylmethyl)-3-[hydroxy-(3-phenyl-propyl)-phosphinoyl]-propionic acid, 2-(amino-pyridin-3-ylmethyl)-N-hydroxy-succinamic acid, 3-(6-amino-pyridin-3-yl)-2-mercaptomethyl-propionic acid, 2-(2-amino-pyridin-4-ylmethyl)-3-mercapto-propionic acid, 2-(6-amino-pyridin-3-ylmethyl)-2-mercaptomethyl-butyric acid, 3-(6-amino-5-methyl-pyridin-3-yl)-2-mercaptomethyl-2-methyl-propionic acid, 3-(6-amino-5-methyl-pyridin-3-yl)-2-mercaptomethyl-propionic acid, 3-(6-amino-4-methyl-pyridin-3-yl)-2-mercaptomethyl-propionic acid, and 3-(6-amino-pyridin-3-yl)-2-mercaptomethyl-butyric acid or a pharmaceutically acceptable salt thereof. The invention is also a method for treating or reducing the risk of inflammation in a patient, or treating or reducing the risk of pain, which comprises treating the patient with a composition comprising an inhibitor of activated thrombin activatable fibrinolysis inhibitor and an NSAID, e.g., a COX-2 inhibitor. Such diseases include but are not limited to nephritis, systemic lupus, erythematosus, rheumatoid arthritis, glomerulonephritis, and sacoidosis.

  该发明涉及治疗或减少患者炎症风险的方法，包括使用活化凝血酶活化的纤溶抑制剂治疗患者。这些疾病包括但不限于肾炎、系统性红斑狼疮、类风湿关节炎、肾小球肾炎和结节病。该发明还涉及治疗或减少患者疼痛风险的方法，包括使用活化凝血酶活化的纤溶抑制剂治疗患者。在这些方法的一类中，活化凝血酶活化的纤溶抑制剂选择自2-(6-氨基吡啶-3-基甲基)-3-丁基琥珀酸、2-(6-氨基吡啶-3-基甲基)-3-苯乙基琥珀酸、2-(6-氨基吡啶-3-基甲基)-3-甲基琥珀酸、2-(6-氨基-5-甲基吡啶-3-基甲基)-3-[(1-苄氧羰基氨基-2-甲基-丙基)羟基磷酰基]-丙酸、2-(6-氨基吡啶-3-基甲基)-3-[羟基-(3-苯基-丙基)-磷酰基]-丙酸、2-(氨基吡啶-3-基甲基)-N-羟基琥酰胺酸、3-(6-氨基吡啶-3-基)-2-巯基甲基丙酸、2-(2-氨基吡啶-4-基甲基)-3-巯基丙酸、2-(6-氨基吡啶-3-基甲基)-2-巯基甲基丁酸、3-(6-氨基-5-甲基吡啶-3-基)-2-巯基甲基-2-甲基丙酸、3-(6-氨基-5-甲基吡啶-3-基)-2-巯基甲基丙酸、3-(6-氨基-4-甲基吡啶-3-基)-2-巯基甲基丙酸和3-(6-氨基吡啶-3-基)-2-巯基甲基丁酸或其药学上可接受的盐。该发明还是一种治疗或减少患者炎症风险，或治疗或减少疼痛风险的方法，包括使用含有活化凝血酶活化的纤溶抑制剂和NSAID（例如COX-2抑制剂）的组合物治疗患者。这些疾病包括但不限于肾炎、系统性红斑狼疮、类风湿关节炎、肾小球肾炎和结节病。
• COMPOSITION CONTAINING AMIDINE DERIVATIVES OR CARBOXAMIDE DERIVATIVES AND STEROIDS, AS A MEDICAMENT
  申请人：Pignol Bernadette

  公开号：US20090149430A1

  公开（公告）日：2009-06-11

  The present invention relates to a composition containing at least one amidine derivative or carboxamide derivative of general formula (I) or (A) in combination with at least one compound chosen from steroids, corticoids or corticosteroids, wherein said composition is suitable for the preparation of a medicament.

  本发明涉及一种含有至少一种氨基甲酸酰胺衍生物或一般式(I)或(A)的羧酰胺衍生物的组合物，与至少一种来自类固醇、皮质类固醇或皮质类固醇的化合物结合在一起，所述组合物适用于制备药物。
• AMIDINE DERIVATIVES AND THEIR APPLICATIONS AS A MEDICAMENT
  申请人：Auvin Serge

  公开号：US20090018120A1

  公开（公告）日：2009-01-15

  The invention concerns amidine derivatives of general formula (I) exhibiting an inhibitory activity of calpains and/or a trapping activity of reactive forms of oxygen.

  这项发明涉及一般式（I）的胍衍生物，其具有钙蛋白酶的抑制活性和/或氧化反应活性的捕捉活性。
• 6 Alpha-methylprednisolone derivatives
  申请人：OHTA SEIYAKU KABUSHIKI KAISHA.

  公开号：EP0095894A2

  公开（公告）日：1983-12-07

  A 6a-methylprednisolone derivative of the general formula: wherein R' is a hydrogen atom or the group where R3 is a straight or once-branched chain C1-4 alkyl group, a phenyl group or a lower alkoxy- or alkylthio-methyl group, and R2 is a straight or once-branched chain C1-4 alkyl group, a phenyl group or a lower alkoxy- or alkylthio-methyl group, with the proviso that when R2 is ethyl group, R1 is not a hydrogen atom or a propionyl group. These compounds exhibit a strong local anti-inflammatory effect and so are useful in external anti-inflammatory preparations for the treatment of various dermal disorders and also as anti-allergic drugs for the treatment of asthma and other allergic diseases.

  通式如下的 6a-甲基泼尼松龙衍生物 其中 R' 是氢原子或基团 其中 R3 是直链或一度支链 C1-4 烷基、苯基或低级烷氧基或烷基硫代甲基，R2 是直链或一度支链 C1-4 烷基、苯基或低级烷氧基或烷基硫代甲基，但当 R2 为乙基时，R1 不是氢原子或丙酰基。 这些化合物具有很强的局部消炎作用，因此可用于治疗各种皮肤病的外用消炎制剂，也可用作治疗哮喘和其他过敏性疾病的抗过敏药物。
• Neue 6alpha-Methylprednisolon-Derivate ihre Herstellung und Verwendung
  申请人：SCHERING AKTIENGESELLSCHAFT

  公开号：EP0112467A1

  公开（公告）日：1984-07-04

  6α-Methylprednisolon-Derivate der allgemeinen Formell worin R1 einen 1-Oxoalkylrest mit 2 bis 6 Kohlenstoffatomen oder einen Benzoylrest und R2 ein Wasserstoffatom, einen 1-Oxoalkylrest mit 2 bis 6 Kohlenstoffatomen oder einen Benzoylrest darstellen, sind pharmakologisch wirksame Substanzen.

  通式中 R1 代表具有 2 至 6 个碳原子的 1-氧代烷基或苯甲酰基，R2 代表氢原子、具有 2 至 6 个碳原子的 1-氧代烷基或苯甲酰基的 6α-甲基泼尼松龙衍生物是具有药理活性的物质。